34 results about "Viral nonstructural protein" patented technology

The invention discloses a monoclonal antibody blocking enzyme-linked immunosorbent assay (ELISA) kit and a method for detecting the nonstructural protein (NSP) antibody of a foot-and-mouth disease virus (FMDV) (FMD NSP B-ELISA); the kit comprises ELISA reaction plates, serum diluent, 25 times concentrated detergent, substrate solution, 100* concentrated ELISA detecting antibody, stop buffer, positive control serum and negative control serum; the ELISA reaction plates are two 96-pore high-affinity ELISA reaction plates, firstly 6* groups of amino acid monoclonal antibody or NSP 2C polyclonal antibody, and then FMDV 3ABC or 2C3AB NSP which is expressed by pronucleus and is provided with 6* groups of amino acid labels is captured through the monoclonal antibody or the polyclonal antibody; and compared with other similar kits, the method has higher coincidence rate and higher positive serum detection rate, and is applicable to detecting the serum of cattle, sheep, pigs and other susceptible animals.

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.

The invention discloses a nonstructural protein antibody ELISA (enzyme-linked immunosorbent assay) kit for a porcine foot-and-mouth disease virus. The kit comprises a foot-and-mouth disease virus nonstructural protein epitope polypeptide coated enzyme-linked reaction plate and an enzyme labeled antibody; foot-and-mouth disease virus nonstructural protein epitope polypeptides are a polypeptide shown as sequence 1, a polypeptide shown as sequence 2, a polypeptide shown as sequence 3 and a polypeptide shown as sequence 4 in a sequence table. According to the kit, a chemically synthesized nonstructural protein antigen peptide is used for coating the reaction plate, antigen dosage is small, sensitivity and specificity are high, and the presence of foot-and-mouth disease virus infection can be effectively detected. The kit provided by the invention has good specificity, sensitivity and high efficiency, and has good market prospect.

The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5' replication recognition sequence, wherein at least one initiation codon has been removed from the 5' replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3' replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5' and 3' replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins.

The present invention describes nucleic acid segments, recombinant alphavirus vectors, and recombinant alphavirus particles that include a Sindbis viral vector. The Sindbis viral vector includes a nucleic acid segment encoding a fusion protein comprising a Sindbis virus nonstructural protein and a protein or peptide of interest, wherein the production of the fusion protein does not affect viral replication or infection. The protein or peptide of interest may be a marker, diagnostic, or therapeutic protein or peptide. Methods of using such recombinant alphavirus particles to kill tumor cells is also described herein.

The invention discloses a preparation method and application of a double-effect vaccine for the dengue fever. The invention provides a protein which is protein a) or protein b, wherein protein a) is a protein composed of an amino acid sequence as shown in a sequence 4 in a sequence table, and protein b) is a protein which has same functions as protein a) and is derived from the protein a) by subjecting the sequence 4 in the sequence table to substitution and/or deletion and/or addition of one or more amino acid residues. Experiments in the invention prove that reconstructed dengue virus non-structural protein 1 (DENV delta NS1) can be used as the vaccine; and the double-effect vaccine can protect mankind or mammals from dengue haemorrhagic fever and block propagation of the dengue virus in nature via mosquitoes.

The invention discloses a detection card for rapidly detecting nonstructural protein antibodies of an FMDV (foot-and-mouth disease virus) in sera. The detection card comprises a detection card housingand a test strip assembled in a detection card housing, wherein the test strip comprises a plastic base plate with a pressure-sensitive adhesive, and a sample pad, a marker pad, a nitrocellulose membrane and absorbent paper are adhered to the base plate in sequence; the marker pad comprises a carrier substrate and a marker, and is a membrane formed by spraying lanthanide fluorescence detection microspheres and lanthanide fluorescence quality control microspheres on the carrier substrate; the nitrocellulose membrane is coated with recombinant protein of FMDV nonstructural protein as a detection line and coated with rabbit anti-chicken lgY antibodies as a control line, and the markers are the fluorescence detection microspheres labeled with FMDV nonstructural protein recombinant antigens and the fluorescence quality control microspheres labeled with chicken lgY antibodies. The detection card can realize rapid detection of the nonstructural protein antibodies of the FMDV on site and in the field and is used for distinguishing virus infection animals from vaccinated animals.

The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.

The present invention relates to a method of elevating prediction accuracy of grouping subjects with severe dengue infection. In the method, a non-structural protein 1 (NS1) and an endogenous anti-NS1 antibody of dengue virus in an ex vivo biological specimen are detected and crossly compared, leading in reduce of false negative rates of testing results, as well as elevating grouping accuracy of patients with severe dengue infection.

The invention provides a crystalline three-dimensional structure of an amino terminal region of an SARS (severe acute respiratory syndrome) coronavirus non-structural protein nsp2. The amino terminal region of the SARS coronavirus non-structural protein nsp2 comprises amino acids at positions in a range of about 1-50 to about 150-300 of the SARS coronavirus non-structural protein nsp2; and atoms in the crystalline three-dimensional structure have at least 40% of atomic coordinates in a table 1, or the average root mean square deviation of the main-chain carbon-skeleton atomic structure coordinates of the at least 40% amino acids of the crystalline three-dimensional structure of the amino terminal region of the SARS coronavirus non-structural protein nsp2 and the coordinates in the table 1 is not greater than 1.5 angstroms. The invention also provides an expression, purification and crystallization method of the SARS coronavirus non-structural protein nsp2, the crystalline structure of the SARS coronavirus non-structural protein nsp2, and theoretic guiding meanings and applications of the crystalline structure in functional researches, latent drug screening and drug designs.

The invention discloses an application of a tiacumicin derivative to preparation of a medicine for treating related diseases and/or symptoms caused by dengue virus infection. Tiacumicin serving as a clostridium difficile infection resisting medicine clinically approved for use is high in safety, and the tiacumicin derivative can remarkably inhibit dengue viruses, is high in activity, has strong binding capacity with dengue virus non-structural protein NS5 and can be expected to be a novel effective dengue virus infection resisting medicine.

The invention discloses an activity determination buffer solution and an activity determination method of high-throughput Zika virus non-structural protease, wherein the buffer solution consists of the following buffer ingredients: 10-200mM of trihydroxymethyl aminomethane, 0-20mM of sodium chloride, 0-1mM of CHAPS, 0-20mM of galactose and glycerol which is 10-40% of in volume percentage, and the pH value of the buffer solution is at 8.0-9.0. The buffer solution provided by the invention can improve the activity of the protease in a process of detecting the enzymatic activity of Zika viruses, so that the high-throughput Zika virus non-structural protease activity determination method, which makes use of the buffer solution, is more accurate in result, and subsequently an effect of guiding the screening of Zika virus protease activity inhibitors is achieved and the research and development progress of medicines targeted to the Zika viruses is promoted.